Is Mercury Biopharmaceutical stock a buy?
What Is The Conclusion?
Right now our advanced algorithms say:
Do the analyst corps agree?
Interesting Questions and Easy Answers!
We cannot find any recorded dividends paid in our systems.
Sorry, we do not have any analyst data for this ticker
We cannot find data for Mercury Biopharmaceutical 10 years ago, but if you had invested on Friday 23rd of December 2022 when the price was TWD11.98, you would have made a profit of TWD1.020 per share or 8.51%
Yes, the average daily trading liquidity for Mercury Biopharmaceutical is TWD392 764 thousand. You should therefore be able to get in and out of your positions relatively fast.
Mercury Biopharmaceutical has a normal ratio of the business financed by loans. This puts the company at some risk in periods of high inflation where borrowing costs usually go up. The company is still not profitable, and high inflation will make it harder to become profitable as costs increase and consumer spending decreases.
We have calculated the inflation risk for Mercury Biopharmaceutical to be high [0.85 of 1]
US inflation for August 2024 was 0.19%. Over the last 12 months, the US inflation is 2.59%. The 10-year treasury yield that indicates the future interest level is currently 4.41 and is up 0.05 over the last 30 days.